Home/Pipeline/Glaucoma Portfolio (Acquired)

Glaucoma Portfolio (Acquired)

Glaucoma

CommercialActive

Key Facts

Indication

Glaucoma

Phase

Commercial

Status

Active

Company

NTC

About NTC

NTC is a private, R&D-focused Italian pharmaceutical company that has established itself as a leading European player in ophthalmic therapeutic solutions. Founded in 1990, the company has achieved significant growth, now distributing over 40 million units annually through a network of over 300 distributors in more than 100 countries. Its strategy is built on internal innovation, strategic acquisitions (like Pharmathen's ophthalmology business), and securing regulatory certifications (MDR for 20 devices) to strengthen its portfolio and market access.

View full company profile

Therapeutic Areas

Ophthalmology Gynecology Gastroenterology Pediatrics

Other Glaucoma Drugs

Drug	Company	Phase	Status
INM-088	InMed Pharmaceuticals	Preclinical	Active
MAN-01	Q BioMed	Pre-clinical	Active
PER-001	Perfuse Therapeutics	Phase 2	Active
hOTX2	BrainEver	Discovery	Active
Glaucoma Treatment	BVI Medical	Commercial	Active
MediPrint Lens (Glaucoma)	MediPrint Ophthalmics	Phase 2b	Active
Glaucoma Program	Broadwing Bio	Pre-clinical	Active
MSC Exosomal Eye Serum	Vitti Labs	Pre-clinical	Active
BTQ1902	Betaliq	Phase 2	Active
TODDD™ Platform	Amorphex Therapeutics	Pre-clinical	Active
Glaucoma Diagnostics	Avellino Laboratories	Development/Accreditation	Active
Glaucoma Portfolio	Visufarma	Commercial	Active